Thanks to the experience accumulated over the last two decades, better patient selection could also improve the results of TIPS. “
“See article in J. Gastroenterol. Hepatol. 2010; 25: 1381–1385. The epithelium Ruxolitinib cell line of the ampulla of Vater has the highest risk of neoplastic transformation in the small bowel.1 Adenomas arising from this site are benign lesions but may progress to malignancy via the adenoma-carcinoma sequence.2 Apart from being premalignant,

some adenomas also harbor foci of malignancy.3,4 Complete removal of these tumors is therefore mandatory. Historically, surgery was the preferred approach but now endoscopy has been shown to be a good alternative first line therapy. Though endoscopic resection of these tumors has been practiced for more than twenty years, there is not yet consensus on the upper limit of the size of tumors suitable for endoscopic resection, the preprocedural staging protocol (endoscopic retrograde cholangiopancreatography Palbociclib concentration (ERCP), endoscopic ultrasonography (EUS), intra-ductal ultrasonography (IDUS), contrast enhanced computed tomography (CECT), magnetic resonance imaging (MRI)), technique of papillectomy, need for biliary sphincterotomy, or timing

of pancreatic stent placement and follow-up of patients after resection.5,6 Although endoscopic resection is safer than surgery, it still carries the risk of early complications like bleeding (2–15%), perforation (0–4%), cholangitis (0–2%) and acute pancreatitis (8–15%), as well as late complications like papillary stenosis (0–8%).7,8 Researchers are constantly striving

to develop technology and techniques to prevent, minimize or effectively handle these complications.9 A number of studies have focused on preventing post-procedure acute pancreatitis. There is growing evidence that prophylactic stent placement in the pancreatic duct decreases this risk.10,11 Unfortunately, most of the evidence is in the form of retrospective data or case series, except for one prospective randomized controlled study which showed a statistically significant decrease in the rate of post-procedure pancreatitis in the stented group.10 On the basis of the above data, prophylactic pancreatic duct stenting during papillectomy is widely practiced. 上海皓元医药股份有限公司 There is, however, no consensus on the type of stent that should be used or the optimal duration of placement. Most endoscopists place a small stent (3–5 Fr) for a short period (3 days).5,12 Some keep the stent in situ until the next surveillance endoscopy (1–2 months) as the pancreatic stent may protect the organ from pancreatitis if resection or thermal ablation is required. Should the pancreatic duct stent be placed before or after the removal of a periampullary tumor? Data indicate that there are problems associated with both pre- and post-procedure stenting.